We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+12.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.14B
AUM Growth
+$2.89M
Cap. Flow
-$226M
Cap. Flow %
-10.56%
Top 10 Hldgs %
48.86%
Holding
120
New
11
Increased
17
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$45.5M
2
SHPG
Shire pic
SHPG
+$33.6M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$20.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.6M
5
VTR icon
Ventas
VTR
+$10.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$42.4M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$32.8M
3
ILMN icon
Illumina
ILMN
+$22.7M
4
AMGN icon
Amgen
AMGN
+$20.2M
5
IPXL
Impax Laboratories, Inc.
IPXL
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
2 Real Estate 4.1%
3 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
101
CALL
Incyte
INCY
$24.2B
– –
-93,500
Closed -$4.59M
MYGN icon
102
CALL
Myriad Genetics
MYGN
$270M
– –
-112,200
Closed -$4.33M
NBIX icon
103
CALL
Neurocrine Biosciences
NBIX
$16.8B
– –
-281,600
Closed -$4.41M
NKTR icon
104
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-22,320
Closed -$4.04M
NKTR icon
105
Nektar Therapeutics
NKTR
$2.39B
– –
-22,320
Closed -$4.04M
RVTY icon
106
Revvity
RVTY
$12.6B
– –
-165,495
Closed -$7.22M
SRPT icon
107
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-345,400
Closed -$7.29M
TEVA icon
108
CALL
Teva Pharmaceuticals
TEVA
$40.8B
– –
-68,600
Closed -$3.69M
UNH icon
109
UnitedHealth
UNH
$376B
– –
-83,186
Closed -$7.17M
ACOR
110
CALL
DELISTED
Acorda Therapeutics
ACOR
– –
-395
Closed -$1.61M
EPZM
111
DELISTED
Epizyme, Inc
EPZM
– –
-141,262
Closed -$3.83M
ALXN
112
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-26,800
Closed -$4.44M
IPXL
113
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-322,600
Closed -$7.65M
THOR
114
DELISTED
THORATEC CORPORATION
THOR
– –
-113,300
Closed -$3.03M
NPSP
115
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-156,000
Closed -$4.06M
CBST
116
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-494,454
Closed -$32.8M
CELG
117
CALL
DELISTED
Celgene Corp
CELG
– –
-180,800
Closed -$17.1M
1 2 3 4
5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Tekla Capital Management held 120 positions worth $2.14B, up 0.14% from $2.13B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Tekla Capital Management withdrew a net $226M in Q4 2014, closing 24 positions and reducing 24 holdings. Its most notable exit was CUBIST PHARMACEUTICALS INC, an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Veradigm Inc. Common Stock worth $20.5M.

  • Tekla Capital Management's largest Q4 2014 buy was Veradigm Inc. Common Stock: 1,604,600 shares worth $20.5M.
  • Tekla Capital Management added most to Biogen in Q4 2014, an estimated $45.5M increase.
  • Tekla Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $42.4M.
  • Tekla Capital Management fully exited CUBIST PHARMACEUTICALS INC in Q4 2014, selling an estimated $32.8M.
  • Tekla Capital Management's ten largest holdings make up 49% of its $2.14B portfolio in Q4 2014.
  • Tekla Capital Management opened 11 new positions and closed 24 in Q4 2014.
  • Tekla Capital Management's portfolio value rose 0.14% quarter-over-quarter to $2.14B.

Based on Tekla Capital Management's 13F filing for Q4 2014, filed 30 Jan 2015.